[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"soft-tissue-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:soft-tissue-neoplasm":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,57,84,119,145,164],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100403501","alpha-radiation-emitters-device-dart-for-the-treatment-of-cutaneous-mucosal-or-superficial-soft-tissue-neoplasia-100403501",false,"NCT04534127","Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia","A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia","Inclusion Criteria:\n\n* Subjects with histopathological confirmation of primary or secondary malignant cutaneous neoplastic lesions, or oral cavity mucosal tumors, or superficial soft tissue sarcoma. Confirmation obtained within 6 months of planned treatment.\n* Subjects with a tumor size ≤ 7 centimeters in the longest diameter.\n* Targetable lesion must be technically amenable for complete coverage (including margins) by the DaRT seeds\n* Brachytherapy indication validated by a multidisciplinary team\n* Patients who have either failed first-line treatment, or are medically unfit for standard of care (surgery, external-beam radiation therapy or chemotherapy), or refuse standard of care.\n* Measurable disease according to RECIST v1.1.\n* Subjects over 18 years old.\n* Subjects' ECOG Performance Status Scale is \\\u003C 2.\n* Subjects' life expectancy is more than 6 months.\n* Platelet count ≥100,000\u002Fmm3.\n* WBC ≥ 3500\u002Fμl, granulocyte ≥ 1500\u002Fμl\n* AST and ALT ≤ 2.5 X ULN\n* International normalized ratio of prothrombin time ≤1.8.\n* Creatinine ≤1.9 mg\u002FdL. Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test and are required to use an acceptable contraceptive method to prevent pregnancy for 3 months after brachytherapy.\n* Subjects are willing to sign an informed consent form.\n\nExclusion Criteria:\n\n* Subject has a tumor of Keratoacanthoma histology.\n* Known hypersensitivity to any of the components of the treatment.\n* Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 12 months.\n* Any medical or psychiatric illness which in the opinion of the investigator would compromise the patient's ability to tolerate this treatment or interfere with the study endpoints.\n* Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids\n* Patient requires treatment which may conflict with the endpoints of this study including evaluation of response or toxicity of DaRT\n* Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.\n* Patients must agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy.\n* High probability of protocol non-compliance (in opinion of investigator).\n* Subjects not willing to sign an informed consent.\n* Women who are pregnant or breastfeeding.","ALL","18 Years",{"count":19,"type":20},56,"ESTIMATED","INTERVENTIONAL",[23],"NA","A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia",[26,27,28],"Skin Cancer","Mucosal Neoplasm of Oral Cavity","Soft Tissue Neoplasm",[30,31,26,32,33,34,35,36,37,38,39,40,41,42,43],"Squamous Cell Carcinoma","SCC","Skin metastasis","HNSCC","Carcinoma, Squamous","CMN","Basal cell carcinoma","Superficial sarcoma","Kaposi sarcoma","Alpha radiation","Cutaneous lesion","Tongue cancer","Lip cancer","Brachytherapy","RECRUITING","2026-06-15",{"date":47,"type":48},"2026-06-16","ACTUAL",{"date":50,"type":48},"2020-12-22",{"date":52,"type":20},"2027-07-01",{"name":54,"class":55},"Alpha Tau Medical LTD.","INDUSTRY",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":21,"phases":66,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":56},"100597708","minibeam-radiation-therapy-with-tungsten-slit-collimator-for-the-treatment-of-recurrent-or-metastatic-skin-or-soft-tissue-tumors-100597708","NCT07062003","Minibeam Radiation Therapy With Tungsten Slit Collimator for the Treatment of Recurrent or Metastatic Skin or Soft Tissue Tumors","A Dose Finding Study of MiniBeam RadioTherapy for Skin and Superficial Soft Tissue Tumors (MBRT1)","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologically confirmed malignancy\n* Primary, recurrent, or metastatic skin or superficial soft tissue tumor amenable to palliative orthovoltage radiotherapy\n* Anticipated life expectancy ≥ 30 days and anticipated capacity for follow up for ≥ 30 days\n* Negative pregnancy test done ≤ 28 days prior to registration, for biological women of childbearing potential only\n* Willing to provide written informed consent\n* Willing to allow baseline and follow up photograph acquisition for response and toxicity assessment\n* Willing and able to return to enrolling institution for follow-up during the active monitoring phase of the study\n* Willing to provide blood and tissue samples for correlative research purposes\n\nExclusion Criteria:\n\n* Hematologic, germ cell, or any other tumor that the investigational team would deem to have a high likelihood of clinical complete response with standard palliative radiotherapy (8 Gy in 1, 30 Gy in 10, etc.)\n* COHORT A (INTACT SKIN) ONLY: Prior radiotherapy targeting the lesion presenting for treatment or prior adjacent radiotherapy if \\> 10 Gy overlaps with a portion of the planned target\n* Treatment with a B-Raf proto-oncogene, serine\u002Fthreonine kinase (BRAF) inhibitor, monoclonal antibodies targeting vascular endothelial growth factor (VEGF) (bevacizumab or ramucirumab) or small molecule inhibitors inhibiting VEGF within the last 2 weeks or planned treatment with BRAF inhibitor within 4 weeks after radiation\n* Treatment with an investigational drug therapy within 2 weeks prior to or 4 weeks (the DLT monitoring period) after MBRT\n* Any tumor with direct extension into the spine such that targeting the spine\u002Fspinal cord could not be avoided",{"count":65,"type":20},60,[23],"This clinical trial tests the safety and best dose of minibeam radiation therapy (MBRT) with a tungsten slit collimator for treating patients with skin or soft tissue tumors that have come back after a period of improvement (recurrent) or that spread from where they first started (primary site) to other places in the body (metastatic). Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Tungsten is an extremely dense metal and is commonly used for blocking x-rays for minimum radiation exposure. A tungsten slit collimator is a device that separates an initially wide beam of x-rays into several very narrow individual beams of radiation. As radiation passes through the collimator, the radiation hits regions of solid tungsten and is blocked. In the open slit regions, radiation passes through to the intended target\u002Ftumor area defined by the physician. The tungsten slit collimator then selectively blocks portions of the radiation to create an alternating pattern of higher \"peak\" and lower \"valley\" radiation dose regions. These narrow beams of radiation are referred to as \"minibeams\" and the general approach referred to as MBRT.",[69,70,71,72,73,28],"Metastatic Malignant Skin Neoplasm","Metastatic Malignant Soft Tissue Neoplasm","Recurrent Malignant Skin Neoplasm","Recurrent Malignant Soft Tissue Neoplasm","Skin Neoplasm","2026-06-02",{"date":76,"type":48},"2026-06-04",{"date":78,"type":48},"2025-08-11",{"date":80,"type":20},"2028-08-01",{"name":82,"class":83},"Mayo Clinic","OTHER",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":91,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":95,"conditions":96,"keywords":107,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":115,"leadSponsor":117,"locationsCount":56},"100640818","studying-the-workflow-of-the-american-college-of-surgeons-geriatric-surgery-program-to-improve-clinical-outcomes-in-older-adults-undergoing-surgery-at-the-james-cancer-hospital-100640818","NCT07606287","Studying the Workflow of the American College of Surgeons Geriatric Surgery Program to Improve Clinical Outcomes in Older Adults Undergoing Surgery at the James Cancer Hospital","Implementation of the American College of Surgeons Geriatric Surgery Verification Program at the James Cancer Hospital","Inclusion Criteria:\n\n1. Patient records for adults aged 65 years or older\n2. Patient records with a surgical encounter or preoperative evaluation within participating James Cancer Hospital surgical oncology services during the rollout period\n3. Patient records with data available in institutional electronic health record or institutional data systems\n4. Clinical staff age 18 years or older who are employed or credentialed at The Ohio State University Wexner Medical Center and work within clinical areas affected by ACS Geriatric Surgery Verification implementation\n\nExclusion Criteria:\n\n1. Patient records for encounters occurring only at outside institutions or non-James hospitals within the enterprise\n2. Patient records missing all primary outcome fields after data quality checks\n3. Clinical staff who are trainees, including medical students, physician assistant students, nursing students, resident physicians, or fellows\n4. Clinical staff whose employment, visa, or institutional status would make participation sensitive under institutional policy, if applicable",true,{"count":93,"type":20},4000,[23],"This study examines how the American College of Surgeons Geriatric Surgery Verification Program, also called the ACS GSV Program, is implemented at the James Cancer Hospital. The program is designed to improve surgical care for adults age 65 and older by helping care teams identify and address age-related needs before, during, and after surgery.\n\nOlder adults with cancer may have concerns related to physical function, memory or thinking, medications, social support, and goals of care. If these needs are not recognized, patients may be at higher risk for complications, longer hospital stays, readmission, or discharge to a facility instead of home.\n\nThe ACS GSV Program includes standards for geriatric surgery leadership, goals-of-care discussions, screening for age-related vulnerabilities, care plans for identified needs, age-friendly perioperative care, and regular review of surgical outcomes. This study will evaluate how well these standards are adopted across surgical oncology services and whether implementation is associated with better outcomes, such as shorter hospital stays, fewer complications, fewer readmissions, and improved discharge outcomes.\n\nThe results may help improve surgical care workflows for older adults undergoing cancer surgery.",[97,98,99,100,101,102,103,104,73,28,105,106],"Breast Carcinoma","Malignant Digestive System Neoplasm","Malignant Female Reproductive System Neoplasm","Malignant Genitourinary System Neoplasm","Malignant Head and Neck Neoplasm","Malignant Nervous System Neoplasm","Malignant Solid Neoplasm","Malignant Thoracic Neoplasm","Central Nervous System Neoplasm","Endocrine Gland Neoplasms",[108,109],"geriatric surgery verification","oncogeriatrics","NOT_YET_RECRUITING","2026-05-27",{"date":113,"type":48},"2026-05-29",{"date":45,"type":20},{"date":116,"type":20},"2027-12-31",{"name":118,"class":83},"Ohio State University Comprehensive Cancer Center",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":125,"targetDuration":127,"studyType":128,"phases":4,"briefSummary":129,"conditions":130,"keywords":133,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":56},"100629081","prospective-registry-of-histotripsy-for-soft-tissue-tumors-100629081","NCT07470008","Prospective Registry of Histotripsy for Soft Tissue Tumors","Inclusion Criteria:\n\n* All adult patients who are treated with histotripsy per standard clinical care at University of California San Francisco (UCSF) are eligible for inclusion in the registry.\n\nExclusion Criteria:\n\n* Children\u002Fminors, and adults who lack decision-making capacity, will be excluded from the registry. Patients who do not consent for inclusion in the registry will also be excluded.",{"count":126,"type":20},200,"3 Years","OBSERVATIONAL","Histotripsy is a treatment that uses focused ultrasound waves to break down tissue without surgery. The ultrasound waves meet at a specific spot and turn the tissue into liquid. This study is a prospective observational registry of participants receiving histotripsy. The goal of this study is to gather information about the use of histotripsy to confirm it is safe and effective medical procedure.",[28,131,132],"Soft Tissue Cancer","Soft Tissue Lesion",[134,135],"Histotripsy","Ablation","2026-03-13",{"date":138,"type":48},"2026-03-17",{"date":140,"type":48},"2026-01-29",{"date":142,"type":20},"2031-08-08",{"name":144,"class":83},"University of California, San Francisco",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":14,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":21,"phases":153,"briefSummary":24,"conditions":154,"keywords":155,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":56},"100354053","alpha-radiation-emitters-device-dart-for-the-treatment-of-cutaneous-mucosal-or-superficial-soft-tissue-neoplasia-100354053","NCT03889899","Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.","Inclusion Criteria:\n\n* Subjects with histopathological confirmation of primary or secondary malignant cutaneous neoplastic lesions, or oral cavity mucosal tumors, or superficial soft tissue sarcoma.\n* Subjects with a tumor size ≤ 7 centimeters in the longest diameter.\n* Measurable disease according to RECIST v1.1.\n* Subjects over 18 years old.\n* Subjects' ECOG Performance Status Scale is \\\u003C 2.\n* Subjects' life expectancy is more than 6 months.\n* Platelet count ≥100,000\u002Fmm3.\n* International normalized ratio of prothrombin time ≤1.8.\n* Creatinine ≤1.9 mg\u002FdL.\n* Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test.\n* Subjects are willing to sign an informed consent form.\n\nExclusion Criteria:\n\n* Subject has a tumor of Keratoacanthoma histology.\n* Patients with significant comorbidities that the treating physician deems may conflict with the endpoints of the study (e.g., poorly controlled autoimmune diseases, vasculitis, etc.)\n* Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids\n* Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.\n* High probability of protocol non-compliance (in opinion of investigator).\n* Subjects not willing to sign an informed consent.\n* Women who are pregnant or breastfeeding.",{"count":152,"type":20},30,[23],[26,27,28],[30,31,26,32,33,34,35,36,37,38,39,40,41,42],"2025-12-01",{"date":158,"type":48},"2025-12-02",{"date":160,"type":48},"2020-10-21",{"date":162,"type":20},"2026-09",{"name":54,"class":55},{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":128,"phases":4,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":56},"100392748","novel-imaging-techniques-for-the-characterization-of-musculoskeletal-tumors-ii-100392748","NCT04394052","Novel Imaging Techniques for the Characterization of Musculoskeletal Tumors II","Novel Imaging Techniques for the Characterization of Musculoskeletal Tumors II: Texture Analysis and Artificial Intelligence","TUMOSTEO II","Inclusion Criteria:\n\n* Patients suspected to have a bone or soft-tissue tumor referred for imaging for initial tumors characterization and staging.\n\nExclusion Criteria:\n\n* Pregnancy\n* Breast feeding patients\n* Renal insufficiency\n* Contra indications to MRI or CT\n* Prior surgery or treatment to the evaluated lesion.",{"count":173,"type":20},740,"This study aims at evaluating the value of various artificial intelligence based techniques to improve the characterization and image post-processing for patients with musculoskeletal tumors.",[28,176],"Bone Neoplasm",[178,179,180,181,182,183],"MRI","CT","Texture analysis","Ultra-high resolution","Tumors","Musculoskeletal","2020-07-20",{"date":186,"type":48},"2020-07-21",{"date":188,"type":48},"2020-06-01",{"date":190,"type":20},"2030-06-01",{"name":192,"class":83},"Central Hospital, Nancy, France"]